Insider Selling: Pro-Dex (NASDAQ:PDEX) CEO Sells $257,422.08 in Stock

Pro-Dex, Inc. (NASDAQ:PDEXGet Free Report) CEO Kirk Richard Lee Van, Jr. sold 4,128 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $62.36, for a total transaction of $257,422.08. Following the transaction, the chief executive officer owned 89,707 shares in the company, valued at approximately $5,594,128.52. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pro-Dex Price Performance

NASDAQ PDEX opened at $67.50 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.14 and a current ratio of 3.67. The firm’s 50 day moving average price is $54.07 and its 200-day moving average price is $45.06. Pro-Dex, Inc. has a 52-week low of $23.47 and a 52-week high of $68.26. The company has a market cap of $215.33 million, a PE ratio of 18.65 and a beta of -0.12.

Pro-Dex (NASDAQ:PDEXGet Free Report) last announced its earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.58. The business had revenue of $19.95 million during the quarter, compared to the consensus estimate of $17.90 million. Pro-Dex had a net margin of 16.08% and a return on equity of 22.78%. Sell-side analysts forecast that Pro-Dex, Inc. will post 3.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on PDEX. Zacks Research raised shares of Pro-Dex to a “hold” rating in a report on Tuesday, May 19th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pro-Dex in a report on Friday, May 1st. Finally, Ascendiant Capital Markets raised their price target on shares of Pro-Dex from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $70.00.

View Our Latest Analysis on Pro-Dex

Institutional Investors Weigh In On Pro-Dex

A number of large investors have recently bought and sold shares of PDEX. Los Angeles Capital Management LLC purchased a new stake in Pro-Dex in the fourth quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Pro-Dex in the second quarter valued at approximately $50,000. AlphaQuest LLC purchased a new stake in Pro-Dex in the third quarter valued at approximately $71,000. Bank of America Corp DE boosted its position in Pro-Dex by 173.3% in the second quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 1,073 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Pro-Dex by 65.4% in the fourth quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock valued at $89,000 after buying an additional 915 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.

Recommended Stories

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.